ReutersAugust 12, 2026Courts
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Reported by Reuters. Read the original →
What the story says
Lilly has filed a lawsuit against six companies, alleging that they are engaged in illegal sales of the experimental obesity drug retatrutide. The details of the lawsuit and the specific claims made against the companies are not provided.
Summarised by a model from Reuters's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
- Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.Human · RCT · 2026
- Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Human · RCT · 2026
- Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.Human · RCT · 2026
What the headline doesn't tell you
- Retatrutide (LY3437943) has 34 studies on file, 10 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.